Related Experiment Video

Updated: Mar 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Alessandra Modena1, Francesco Massari2, Chiara Ciccarese1

  • 1Medical Oncology, Azienda Ospedaliera Universitaria Integrata (AOUI), University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.

Targeted Oncology
|February 6, 2016
PubMed

Insights

Targeting MET and VEGFR pathways shows promise for metastatic castration-resistant prostate cancer (mCRPC) bone metastases. While current agents offer modest benefits, further research into the MET/VEGFR axis is ongoing.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) management, particularly bone metastases, requires improved therapies.
  • The MET receptor tyrosine kinase and vascular endothelial growth factor receptor (VEGFR) are implicated in prostate cancer progression and bone pathology.

Purpose of the Study:

  • To review the rationale for targeting the MET and VEGFR pathways in mCRPC.
  • To summarize available clinical data and ongoing trials for MET/VEGFR inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of data from trials investigating MET and VEGFR inhibitors in mCRPC.

Main Results:

  • Agents targeting MET and/or VEGFR pathways have shown modest activity in mCRPC.
  • No significant improvement in overall survival has been observed with current agents.
  • The MET/VEGFR axis remains an area of active research interest.

Conclusions:

  • Targeting the MET/VEGFR axis is a promising strategy for mCRPC, especially for bone metastases.
  • Further investigation is needed to optimize therapeutic approaches and improve patient outcomes.
  • Understanding the mechanisms of MET/VEGFR inhibitors is crucial for future drug development.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K